# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Non-squamous non-small cell lung cancer, METex14 skipping alteration, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy (NHS England policy) or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/ta181) (NHS England policy) or
* pemetrexed and carboplatin (NHS England policy) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/ta181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet therapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), and who have disease progression after platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).